Targeting protein kinases for anti-glioma treatment
Emanuela Pucko1, Robert Ostrowski1
1Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Abstract:
The genetic alterations related to many kinases are responsible for the formation of glial tumours. In addition it is the cell kinases that keep the cancerous signalling machinery in motion, thus enabling tumour cell growth, motility and invasion. Kinase inhibitors may have a potential to surpass the classical oncolytic treatment for gliomas. However, overcoming drug resistance mechanisms and limited blood-brain barrier (BBB) permeability are the remaining daunting issues. Latest research explores novel kinase inhibitors, yielding several promising results, including those from CK2 inhibition studies, as well as the possibility of relabelling the inhibitors previously approved for tumours other than glial tumours.
Insights
Kinase inhibitors show promise for treating gliomas by targeting cancer cell signaling. Research is exploring novel inhibitors and repurposing existing drugs to overcome challenges like drug resistance and blood-brain barrier penetration.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Genetic alterations in kinases drive glial tumor formation and progression.
- Cellular kinases sustain the signaling pathways essential for tumor growth, motility, and invasion.
Purpose of the Study:
- To explore novel kinase inhibitors for glioma treatment.
- To investigate the potential of repurposing existing kinase inhibitors for gliomas.
- To address challenges in drug resistance and blood-brain barrier (BBB) permeability.
Main Methods:
- Review of recent research on kinase inhibitors in glioma.
- Analysis of CK2 inhibition studies.
- Exploration of drug repurposing strategies for approved kinase inhibitors.
Main Results:
- Novel kinase inhibitors demonstrate promising anti-glioma activity.
- CK2 inhibition presents a potential therapeutic avenue.
- Repurposing approved kinase inhibitors offers a viable strategy.
Conclusions:
- Kinase inhibitors represent a promising alternative to traditional glioma treatments.
- Overcoming drug resistance and achieving BBB penetration are key challenges.
- Targeting kinases, including CK2, and repurposing drugs hold significant potential for advancing glioma therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22PI3K/mTOR/AKT Signaling Pathway